Cytokinetics Announces Board and Executive Changes
Ticker: CYTK · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $50,000, $12,500, $440,000, $700,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: CYTK
TL;DR
Cytokinetics board and exec comp shake-up effective Feb 10, 2025.
AI Summary
Cytokinetics, Incorporated announced on February 10, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its key executives. These changes are effective as of February 10, 2025.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance.
Key Players & Entities
- Cytokinetics, Incorporated (company) — Registrant
- February 10, 2025 (date) — Date of earliest event reported
- 350 Oyster Point Boulevard (location) — Principal Executive Offices Address
- South San Francisco, California (location) — Principal Executive Offices City and State
- 94080 (location) — Principal Executive Offices Zip Code
- (650) 624-3000 (phone_number) — Registrant's Telephone Number
FAQ
What specific items are being reported in this Form 8-K?
This Form 8-K reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is February 10, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 350 Oyster Point Boulevard, South San Francisco, California, 94080.
What is the Registrant's telephone number?
The Registrant's telephone number, including area code, is (650) 624-3000.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 820 words · 3 min read · ~3 pages · Grade level 12.7 · Accepted 2025-02-11 07:30:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
- $50,000 — comprised of: (i) an annual retainer of $50,000 for his service on the Board commencing
- $12,500 — of service, (ii) an annual retainer of $12,500 for his service on the Board's Audit Co
- $440,000 — n stock with a grant date fair value of $440,000, the stock options of which will vest m
- $700,000 — options with a grant date fair value of $700,000. The Initial Grant will vest monthly ov
Filing Documents
- cytk-20250210.htm (8-K) — 43KB
- 0000950170-25-017458.txt ( ) — 154KB
- cytk-20250210.xsd (EX-101.SCH) — 24KB
- cytk-20250210_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: February 11, 2025 By: /s/ John O. Faurescu John O. Faurescu, Esq. Secretary